Document is current

Article History

Received: 14 January 2025

Accepted: 19 March 2025

First Online: 2 April 2025

Declarations

:

: The trial was approved by the Ethics Committee of the University of Muenster (reference number 2024-568-f-S). Informed consent was waived owing to the retrospective nature of the study.

: All authors agree to the publication of this work.

: KG has worked as advisory board member for Amgen, Novartis and Daiichi-Sankyo and received honoraria from Amgen, Bayer Vital, Daiichi-Sankyo, Novartis, Sanofi Aventis and Amarin, all outside the submitted work. NM reports speaker honoraria and travel support from BARD and Bayer Vital GmbH, outside the submitted work. HR has received speaker honoraria from NeoVasc, Corvia, MedUpdate, StremedUp, and NovoNordiks. He has acted as a consultant for Daiichi Sankyo, Pfizer, DiaPlan, and Pluristem receiving in part also financial compensations for this work. His division within the University Hospital of Muenster has taken or is still taking part in multicentre trials of BARD, BMS/Pfizer, BIOTRONIK, and Pluristem receiving patient fees and financial compensation for these efforts. All honoraria, research grants, fees and financial compensations were received outside the submitted work. All other authors have nothing to declare.